Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
Y-39983
print preview
bookmark
share with colleague
General Information
Company
Mitsubishi Tanabe Pharma Corp.
Description
Rho kinase (ROCK) inhibitor
Molecular Target
Rho kinase
Mechanism of Action
Rho kinase inhibitor
Latest Stage of Development
Phase II
Indication
Glaucoma
Partner
Novartis AG
;
Senju Pharmaceutical Co. Ltd.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy